DelveInsight’s “Osteosarcoma Market Insight, Epidemiology and Market Forecast – 2034” report offers an in-depth understanding of Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Osteosarcoma, offering comprehensive insights into the Osteosarcoma revenue trends, prevalence, and treatment landscape. The report delves into key Osteosarcoma statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Osteosarcoma therapies. Additionally, we cover the landscape of Osteosarcoma clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Osteosarcoma treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Osteosarcoma space.
To Know in detail about the Osteosarcoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Osteosarcoma Market Forecast https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=mpr
Some of the key facts of the Osteosarcoma Market Report:
- The Osteosarcoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
- In September 2025, OS Therapies announced progress on its OST-HER2 program for recurrent pulmonary metastatic osteosarcoma after a productive FDA End of Phase 2 meeting, with plans to begin rolling a Biologics Licensing Application (BLA) submission that month.
- In January 2025, GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, received the Breakthrough Therapy Designation from US FDA in late-line relapsed or refractory osteosarcoma.
- In March 2025, Y-mAbs Therapeutics announced new data from a Phase II clinical trial evaluating naxitamab with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed/refractory high-risk neuroblastoma and residual disease in the bone/bone marrow.
- In November 2024, Y-mAbs Therapeutics announced that they have entered into an exclusive license and distribution agreement for the development and commercialization in Japan of DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and, upon agreement by the parties, potentially relapsed osteosarcoma.
- Approximately 20–30% of patients with localized (non-metastatic) osteosarcoma and up to 80% of those with metastatic disease eventually develop relapsed or refractory osteosarcoma.
- Among the 7MM, the United States has captured the highest market share of osteosarcoma in 2024.
- Among all the subtype specific cases, around 80% were of conventional osteosarcoma in 2024, while chondroblastic accounted for ~5% of the total population share.
- Osteosarcoma is more common in males as compared to females.
- Osteosarcoma is more common in children, teens, and young adults between the ages of 10 and 30, and only 1 in 10 osteosarcomas occur in people older than 60.
- In the US, the femur accounted for the highest proportion of site-specific incident cases, while tibia occupied the bottom of the ladder.
- Key Osteosarcoma Companies: Takeda Pharmaceuticals, OS Therapies, Y-mAbs Therapeutics, AlaMab Therapeutics, CSPC Pharmaceutical, MedPacto, Hansoh Pharmaceutical, Takeda, Acrotech Biopharma, Bayer, Exelixis, Nektar Therapeutics, Eisai, GlaxoSmithKline/Novartis, Aadi Bioscience, Vaccinex, Inc., National Cancer Institute/Assaf-Harofeh Medical Center, Eleison Pharmaceuticals, Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech, and others
- Key Osteosarcoma Therapies: MEPACT (mifamurtide), OST-HER2 (OST31-154), DANYELZA (naxitamab 15-096), Vactosertib, ALMB-0168, HS-20093, and others
- The Osteosarcoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteosarcoma pipeline products will significantly revolutionize the Osteosarcoma market dynamics.
Osteosarcoma Overview
Osteosarcoma, also known as osteogenic sarcoma, is the most common type of bone cancer that originates from bone-forming cells that become cancerous and produce abnormal bone tissue. It usually develops in the long bones of the arms or legs, especially near the knee or shoulder. It predominantly affects children, teenagers and young adults, especially when their bones are growing rapidly. Osteosarcoma is highly heterogeneous in its manifestation, which permits division into several subtypes according to the degree of differentiation, location within the bone, and histological variation. Individuals with osteosarcoma might experience bone pain, swelling, and fractures. It is caused due to complex genetic alterations, including mutations in tumor suppressor genes. Treatment typically involves a combination of surgery, chemotherapy, and radiation therapy, though prognosis varies significantly based on disease stage and metastatic status.
Get a Free sample for the Osteosarcoma Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=mpr
Osteosarcoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Osteosarcoma Epidemiology Segmentation:
The Osteosarcoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
- Total Incident Cases of Osteosarcoma in the 7MM
- Site-specific Cases of Osteosarcoma in the 7MM
- Sub-types specific Cases of Osteosarcoma in the 7MM
- Stage-specific Cases of Osteosarcoma in the 7MM
- Age-specific Cases of Osteosarcoma in the 7MM
- Gender-specific Cases of Osteosarcoma in the 7MM
Download the report to understand which factors are driving Osteosarcoma epidemiology trends @ Osteosarcoma Epidemiology Forecast https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=mpr
Osteosarcoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteosarcoma market or expected to get launched during the study period. The analysis covers Osteosarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Osteosarcoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Osteosarcoma Therapies and Key Companies
Marketed Therapy:
- MEPACT (mifamurtide): Takeda Pharmaceuticals
Emerging Therapies:
- OST-HER2 (OST31-154): OS Therapies
- DANYELZA (naxitamab 15-096): Y-mAbs Therapeutics
- ALMB-0168: AlaMab Therapeutics and CSPC Pharmaceutical
- Vactosertib: MedPacto
- HS-20093: Hansoh Pharmaceutical
Discover more about therapies set to grab major Osteosarcoma market share @ Osteosarcoma Treatment Landscape https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=mpr
Osteosarcoma Market Drivers
- Rising Incidence in Pediatric and Adolescent Populations – Osteosarcoma remains one of the most common primary bone cancers in children and young adults, sustaining long-term treatment demand
- Growing Adoption of Combination Therapies – Increased use of multimodal treatment approaches such as chemotherapy, surgery, and targeted therapies is expanding the therapeutic landscape
- Advances in Immunotherapy and Precision Medicine – Ongoing research into CAR-T cells, immune checkpoint inhibitors, and biomarker-based treatments is fueling innovation and clinical trial activity
- Improved Diagnostic and Imaging Technologies – Enhanced MRI, PET-CT, and biopsy techniques allow earlier detection and better monitoring of tumor progression and metastasis
- Rising Investments and Collaborations in Oncology R&D – Government grants, pharma-biotech partnerships, and orphan drug designations are accelerating drug development for this rare cancer
- Breakthrough Therapy Designations and Regulatory Support – Recent FDA designations for emerging therapies are expediting the approval pathway for novel treatments
Osteosarcoma Market Barriers
- Limited Treatment Options for Relapsed/Refractory Disease
- Poor Prognosis for Metastatic Osteosarcoma
- High Treatment Costs
- Limited Patient Pool for Clinical Trials
- Challenges in Drug Development Despite Decades of Research
- Tumor Heterogeneity Complicating Targeted Therapy Development
Scope of the Osteosarcoma Market Report
- Study Period: 2020-2034
- Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
- Key Osteosarcoma Companies: Takeda Pharmaceuticals, OS Therapies, Y-mAbs Therapeutics, AlaMab Therapeutics, CSPC Pharmaceutical, MedPacto, Hansoh Pharmaceutical, Acrotech Biopharma, Bayer, Exelixis, Nektar Therapeutics, Eisai, GlaxoSmithKline/Novartis, Aadi Bioscience, Vaccinex, Inc., National Cancer Institute/Assaf-Harofeh Medical Center, Eleison Pharmaceuticals, Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech, and others
- Key Osteosarcoma Therapies: MEPACT (mifamurtide), OST-HER2 (OST31-154), DANYELZA (naxitamab 15-096), Vactosertib, ALMB-0168, HS-20093, and others
- Osteosarcoma Therapeutic Assessment: Osteosarcoma current marketed and Osteosarcoma emerging therapies
- Osteosarcoma Market Dynamics: Osteosarcoma market drivers and Osteosarcoma market barriers
- Competitive Intelligence Analysis: SWOT analysis, Conjoint analysis, Porter’s five forces, Market entry strategies
- Osteosarcoma Unmet Needs, KOL’s views, Analyst’s views, Osteosarcoma Market Access and Reimbursement
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Contact No.: +14699457679
Address: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
